Aminoferrocene-based prodrugs activated by reactive oxygen species

Cancer cells generally generate higher amounts of reactive oxygen species than normal cells. On the basis of this difference, prodrugs have been developed (e.g., hydroxyferrocifen), which remain inactive in normal cells, but become activated in cancer cells. In this work we describe novel aminoferro...

Full description

Saved in:
Bibliographic Details
Main Authors: Hagen, Helen (Author) , Marzenell, Paul David (Author) , Jentzsch, Elmar (Author) , Wenz, Frederik (Author) , Veldwijk, Marlon Romano (Author) , Mokhir, Andriy (Author)
Format: Article (Journal) Chapter/Article
Language:English
Published: December 19, 2011
In: Disparate SAR data of Griseofulvin analogues for the dermatophytes trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells
Year: 2012, Volume: 55, Issue: 2, Pages: 924-934
DOI:10.1021/jm2014937
Online Access:Verlag, Volltext: http://dx.doi.org/10.1021/jm2014937
Verlag, Volltext: http://pubs.acs.org/doi/10.1021/jm2014937
Get full text
Author Notes:Helen Hagen, Paul Marzenell, Elmar Jentzsch, Frederik Wenz, Marlon R. Veldwijk, and Andriy Mokhir
Description
Summary:Cancer cells generally generate higher amounts of reactive oxygen species than normal cells. On the basis of this difference, prodrugs have been developed (e.g., hydroxyferrocifen), which remain inactive in normal cells, but become activated in cancer cells. In this work we describe novel aminoferrocene-based prodrugs, which, in contrast to hydroxyferrocifen, after activation form not only quinone methides (QMs), but also catalysts (iron or ferrocenium ions). The released products act in a concerted fashion. In particular, QMs alkylate glutathione, thereby inhibiting the antioxidative system of the cell, whereas the iron species induce catalytic generation of hydroxyl radicals. Since the catalysts are formed as products of the activation reaction, it proceeds autocatalytically. The most potent prodrug described here is toxic toward cancer cells (human promyelocytic leukemia (HL-60), IC50 = 9 μM, and human glioblastoma-astrocytoma (U373), IC50 = 25 μM), but not toxic (up to 100 μM) toward representative nonmalignant cells (fibroblasts).
Item Description:Gesehen am 03.05.2018
Physical Description:Online Resource
DOI:10.1021/jm2014937